ALLMedicine™ Cholangiocarcinoma Center

Mar 2nd, 2021 - Stereotactic ablative body radiation therapy (SABR) is a well-established alternative to surgery for early stage non-small-cell lung cancer (NSCLC). While SABR is typically delivered in 3 to 5 fractions, randomized trials have shown single-fractio...

Mar 2nd, 2021 - Cholangiocarcinoma (CC) is a rare tumour arising from the biliary tract epithelium. The aim of this study was to perform a genomic characterisation of CC tumours and to implement a model to differentiate extrahepatic (ECC) and intrahepatic (ICC) c...

Mar 2nd, 2021 - Elevated fibrinogen (Fbg) levels contribute to tumor progression and metastasis. However, little is known regarding the association of the clinicopathological characteristics and the prognosis of hilar cholangiocarcinoma (HC) with plasma fibrinoge...

Mar 2nd, 2021 - Recent studies suggest red blood cell distribution width (RDW) was a prognostic factor in various types of cancer patients, although the results are controversial. The objective of this study was to investigate the significance of RDW in patients ...

Mar 2nd, 2021 - Cholangiocarcinoma is a highly malignant cancer with very dismal prognosis. Perihilar cholangiocarcinoma(pCCA) accounts for more than 50% of all cholangiocarcinoma and is well-characterized for its low rate of radical resection. Effects of radioth...

Jul 15th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

Mar 2nd, 2021 - Stereotactic ablative body radiation therapy (SABR) is a well-established alternative to surgery for early stage non-small-cell lung cancer (NSCLC). While SABR is typically delivered in 3 to 5 fractions, randomized trials have shown single-fractio...

Mar 2nd, 2021 - Cholangiocarcinoma (CC) is a rare tumour arising from the biliary tract epithelium. The aim of this study was to perform a genomic characterisation of CC tumours and to implement a model to differentiate extrahepatic (ECC) and intrahepatic (ICC) c...

Mar 2nd, 2021 - Elevated fibrinogen (Fbg) levels contribute to tumor progression and metastasis. However, little is known regarding the association of the clinicopathological characteristics and the prognosis of hilar cholangiocarcinoma (HC) with plasma fibrinoge...

Mar 2nd, 2021 - Recent studies suggest red blood cell distribution width (RDW) was a prognostic factor in various types of cancer patients, although the results are controversial. The objective of this study was to investigate the significance of RDW in patients ...

Mar 2nd, 2021 - Cholangiocarcinoma is a highly malignant cancer with very dismal prognosis. Perihilar cholangiocarcinoma(pCCA) accounts for more than 50% of all cholangiocarcinoma and is well-characterized for its low rate of radical resection. Effects of radioth...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Feb 19th, 2020 - Figure 1. Common bile duct and pancreatic duct Perihilar tumors, also called Klatskin tumors, are the most common cholangiocarcinomas. They occur in the hilum region at the bifurcation of the right and left hepatic ducts. Intrahepatic tumors are t...

Feb 19th, 2020 - Even though the rates of resection with tumor-free margins have improved with more aggressive surgical approaches and improved radiologic techniques, recurrence rates remain high (49%-64%). These recurrences usually occur within 2-3 years post-res...